More on APRE
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.92 |
|
|||
| Open | $0.89 | ||||
| 52 Wk High | $0.08 | ||||
| 52 Wk Low | $0.00 | ||||
| Day High | $0.94 | ||||
| Day Low | $0.87 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 103,069 | ||||
- Form S-3 Aprea Therapeutics, Inc.
- Form 8-K Aprea Therapeutics, Inc. For: Feb 18
- Aprea reports second partial response in cancer drug trial
- Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
- Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: Nantahala Capital Management, LLC
- Aprea Therapeutics expands patent portfolio for cancer drugs through 2045
- Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
- Aprea Therapeutics names Eugene Kennedy as chief medical advisor
- Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
Entities mentioned with APRE
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maxim Group | View Related Stories »
- S3 | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
